Vanda Pharmaceuticals Inc. (VNDA) announced that the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis.Shares of the company were down 6.1% on Sept. 19 following the announcement of the news.Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach's ability to empty its contents. The FDA has not approved any effective medicine for tre ...